Balixafortide (POL6326) is a cyclic peptide CXCR4 antagonist primarily used in oncology research. It is being investigated for its potential to enhance the efficacy of chemotherapy, particularly in treating metastatic breast cancer. By blocking the CXCR4 receptor, it inhibits cancer cell migration, invasion, and metastasis, while also disrupting the tumor microenvironment, including angiogenesis. Additionally, it is explored in combination therapies to improve the mobilization of hematopoietic stem cells for transplantation in patients with hematological disorders. Currently in clinical development, it shows promise for innovative cancer treatment strategies.